Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy

Polymorphisms contribute to inter-individual differences and show a promising predictive role for chemotherapy-related toxicity in colon cancer (CC). TOSCA is a multicentre, randomized, non-inferiority, phase III study conducted in high-risk stage II/stage III CC patients treated with 6 vs 3 months...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Rep
Egile Nagusiak: Ruzzo, Annamaria, Graziano, Francesco, Galli, Francesca, Galli, Fabio, Rulli, Eliana, Lonardi, Sara, Ronzoni, Monica, Massidda, Bruno, Zagonel, Vittorina, Pella, Nicoletta, Mucciarini, Claudia, Labianca, Roberto, Ionta, Maria Teresa, Bagaloni, Irene, Veltri, Enzo, Sozzi, Pietro, Barni, Sandro, Ricci, Vincenzo, Foltran, Luisa, Nicolini, Mario, Biondi, Edoardo, Bramati, Annalisa, Turci, Daniele, Lazzarelli, Silvia, Verusio, Claudio, Bergamo, Francesca, Sobrero, Alberto, Frontini, Luciano, Magnani, Mauro
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6687727/
https://ncbi.nlm.nih.gov/pubmed/31395900
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-47627-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak